An interventional study of 0.243% sodium fluoride and toothbrush in Gingivitis and Pregnancy, sponsored by Procter and Gamble. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Procter and Gamble · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.
Among the 23 studies testing Tin Fluorides in Gingivitis, this one has the largest enrollment, is the only one that started in 2012, is one of 10 with no phase, and was the 1st registered.
631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.
Browse Gingivitis studies →1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:
Colgate Palmolive
Ages 60+ · Healthy volunteers
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2012.
This study's enrollment of 746 is above the median of 66 across 507 interventional studies indexed under Gingivitis.
Median enrollment 115 across the 23 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 23 have an industry lead sponsor. The 6 most frequent:
Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
22 studies in Gingivitis by Procter and Gamble: none open now, 2 under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 22 studies in Gingivitis by Procter and Gamble, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 10 with no phase, and was the 3rd registered.
Procter and Gamble’s Gingivitis studies by the year they started, since 2009.
1 of the studies testing Tin Fluorides in Gingivitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07807397Colgate PalmoliveOral Hygiene Assistance Training Program | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing Tin Fluorides in Gingivitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Procter and Gamble’s 22 in Gingivitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will track changes in oral health in pregnant women. Subjects will be assigned to either regular oral care or advanced oral care and be given oral care products to use until they deliver. A comparison between the two groups (regular and advanced oral care) will be made to see if the oral care products impacted oral health and maternity variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
toothpaste, toothbrush and dental floss
Drug: 0.243% sodium fluoride · Device: toothbrush · Device: dental floss
toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
Drug: 0.454% stannous fluoride · Device: toothbrush · Drug: 0.07% Cetylpyridinium chloride · Device: dental floss
dentifrice: brush thoroughly twice daily
Also known as: Crest® Cavity Protection toothpaste
brush thoroughly twice daily
Also known as: Oral-B® Indicator toothbrush, regular, soft
floss the whole mouth once daily
Also known as: Oral-B® Essentials dental floss
dentifrice: twice daily brush thoroughly for 2 minutes
Also known as: Crest® Pro-Health toothpaste
twice daily brush thoroughly for 2 minutes
Also known as: Oral-B® ProfessionalCare Series 1000 toothbrush, Oral-B® Precision Clean brush head
mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
Also known as: Crest® Pro-Health Multi-Protection Mouth Rinse
floss the whole mouth once daily
Also known as: Glide® Pro-Health Deep Clean dental floss
Change From Baseline in Löe-Silness Gingivitis Index
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
Time frame: 3 months
Change From Baseline in Löe-Silness Gingivitis Index
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
Time frame: 2 months
Change From Baseline in Löe-Silness Gingivitis Index
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
Time frame: 1 month
Gestational Age (Weeks)
log\[42.9-gestational age\]
Time frame: At delivery
Neonate Birth Weight (Grams)
Time frame: At delivery
Preterm Birth (Gestational Age < 37 Weeks)
Time frame: At delivery
| Milestone | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Started | 373 | 373 |
| Completed | 334 | 336 |
| Not completed | 39 | 37 |
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
| score on a scale | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Change From Baseline in Löe-Silness Gingivitis Index | 0.141 ± 0.0046 | 0.154 ± 0.0046 |
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
| score on a scale | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Change From Baseline in Löe-Silness Gingivitis Index | 0.124 ± 0.0044 | 0.137 ± 0.0045 |
Score Criteria 0 Normal gingiva. 1. Mild inflammation - slight change in color, slight edema. No bleeding on probing. 2. Moderate inflammation - redness, edema, and glazing. Bleeding on probing. 3. Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding.
| score on a scale | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Change From Baseline in Löe-Silness Gingivitis Index | 0.112 ± 0.0045 | 0.125 ± 0.0045 |
log\[42.9-gestational age\]
| log weeks | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Gestational Age (Weeks) | 1.3988 ± 0.03394 | 1.3271 ± 0.03403 |
| grams | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Neonate Birth Weight (Grams) | 3095.97 ± 46.588 | 3167.80 ± 45.955 |
| Participants | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| Preterm Birth (Gestational Age < 37 Weeks) | 32 | 21 |
Collected over Participants were enrolled 8-24 weeks into pregnancy until delivery. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regular Oral Hygiene | 0/373 (0%) | 79/373 (21.2%) | 353/373 (94.6%) |
| Advanced Oral Hygiene Plus Counseling | 0/373 (0%) | 75/373 (20.1%) | 329/373 (88.2%) |
| Event | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| PREMATURE DELIVERYPregnancy, puerperium and perinatal conditions | 27/373 | 15/373 |
| PRE-ECLAMPSIAPregnancy, puerperium and perinatal conditions | 21/373 | 12/373 |
| CHORIOAMNIONITISInfections and infestations | 14/373 | 10/373 |
| PREMATURE RUPTURE OF MEMBRANESPregnancy, puerperium and perinatal conditions | 9/373 | 7/373 |
| GESTATIONAL HYPERTENSIONPregnancy, puerperium and perinatal conditions | 8/373 | 7/373 |
| FOETAL GROWTH RESTRICTIONPregnancy, puerperium and perinatal conditions | 1/373 | 7/373 |
| PREMATURE LABOURPregnancy, puerperium and perinatal conditions | 6/373 | 7/373 |
| STILLBIRTHPregnancy, puerperium and perinatal conditions | 4/373 | 3/373 |
| VAGINAL HAEMORRHAGEReproductive system and breast disorders | 4/373 | 3/373 |
| BLOOD PRESSURE INCREASEDInvestigations | 3/373 | 1/373 |
| Event | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling |
|---|---|---|
| STREPTOCOCCUS TEST POSITIVEInvestigations | 88/373 | 94/373 |
| ANAEMIABlood and lymphatic system disorders | 35/373 | 41/373 |
| PREMATURE DELIVERYPregnancy, puerperium and perinatal conditions | 40/373 | 28/373 |
| URINARY TRACT INFECTIONInfections and infestations | 27/373 | 18/373 |
| GESTATIONAL DIABETESPregnancy, puerperium and perinatal conditions | 25/373 | 17/373 |
| CHORIOAMNIONITISInfections and infestations | 24/373 | 22/373 |
| VULVOVAGINAL MYCOTIC INFECTIONInfections and infestations | 21/373 | 24/373 |
| PRE-ECLAMPSIAPregnancy, puerperium and perinatal conditions | 23/373 | 15/373 |
| NAUSEAGastrointestinal disorders | 18/373 | 19/373 |
| VOMITINGGastrointestinal disorders | 14/373 | 19/373 |
| Age, Continuous(years) | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling | Total |
|---|---|---|---|
| Mean | 27.6 ± 5.89 | 27.4 ± 6.01 | 27.46 ± 5.945 |
| Sex: Female, Male(Participants) | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling | Total |
|---|---|---|---|
| Female | 373 | 373 | 746 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Regular Oral Hygiene | Advanced Oral Hygiene Plus Counseling | Total |
|---|---|---|---|
| American Indian | 2 | 0 | 2 |
| Asian Oriential | 8 | 15 | 23 |
| Black | 260 | 262 | 522 |
| Caucasian | 76 | 77 | 153 |
| Hispanic | 13 | 10 | 23 |
| Asian Indian | 6 | 4 | 10 |
| Multi-racial | 8 | 5 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Feb 2012, a primary completion of Feb 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2020, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tin Fluorides · Cetylpyridinium